Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-28
2011-06-28
Kosack, Joseph (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S317000, C514S332000, C514S361000, C514S370000, C514S383000, C514S396000, C514S447000, C514S461000, C544S330000, C546S194000, C546S309000, C548S134000, C548S146000, C548S262600, C548S328100, C549S063000, C549S480000
Reexamination Certificate
active
07968560
ABSTRACT:
Novel compounds having the general formula (I) below:are useful in a wide variety of applications in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively are formulated into cosmetic compositions.
REFERENCES:
patent: 6699904 (2004-03-01), Hayward et al.
patent: 6927228 (2005-08-01), Bernardon et al.
patent: 1 216 980 (2002-06-01), None
patent: WO 02/12210 (2002-02-01), None
patent: WO 2004/024939 (2004-03-01), None
M.M.T. Downie et al., “Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro”, British Journal of Dermatology, 2004: 151: 766-775, published by Blackwell Publishing, UK.
Ramona Behshad et al., “A Retrospective Case Series Review of the Peroxisome Proliferator-Activated Receptor Ligand Rosiglitazone in the Treatment of Atopic Dermatitis,” Arch Dermatol. 2008; 144(1):84-88, published by AMA, Chicago, IL, US.
Tamar Nijsten et al., “Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors,” Journal of Cutaneous Pathology, 2005: 32:340-347, published by Blackwell Munksgaard, Denmark.
Joong Sun Lee et al., “PPAR-gamma agonist, ciglitazone, increases pigmentation and migration of human melanocytes,” Experimental Dermatology, 2007, 16, 118-123, published by Blackwell Munksgaard, Denmark.
James Varani et al. “Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease,” Expert Opin. Investig. Drugs, 2006, 15(11):1453-1468, published by Informa HealthCare, UK.
George Patani et al., “Bioisosterism: A Rational Approach in Drug Design,” Chem.Rev. 1996, vol. 96, No. 8, pp. 3147-3176, American Chemical Society, US.
Aubert Jerome
Chantalat Laurent
Clary Laurence
Rivier Michel
Thoreau Etienne
Buchanan Ingersoll & Rooney P.C.
Galderma Research & Development
Kosack Joseph
LandOfFree
Compounds that modulate PPARγ-type receptors and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds that modulate PPARγ-type receptors and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds that modulate PPARγ-type receptors and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2695372